Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages.

From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

Watch on-demand expert soundbites recorded at the April 2025 ADVENT Forum in Lisbon, Portugal, featuring dermatology and immunology perspectives on mechanisms and clinical practice. Topics range from disease mechanism to patient care and quality of life, spanning atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

Drs. Elmariah, Kim, and Metz explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.

Dr. Casale discusses delays in diagnosing CSU, the impact of severe itch on daily life and mental health, and the challenges in achieving remission.

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga discusses data identifying atopic dermatitis as the first diagnosed atopic disease and the start of the atopic march.
Dr. Elena Netchiporouk illustrates key considerations for diagnosing CSU at EADV 2025.
This is the ADVENT-branded video of the IDEF presentation that was presented during the 1-hour webinar on December 1st featuring both Dr. Sarina Elmariah and Dr. Jason Hawkes.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares describes how IL-4 is the key cytokine involved in the initiation and perpetuation of Th2 cell responses and type 2 inflammation.